DWP
CVKD icon

Destiny Wealth Partners’s Cadrenal Therapeutics CVKD Stock Holding History

Destiny Wealth Partners’s Portfolio CVKD Stock Details CVKD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.02K Buy
+200
New +$1.4K ﹤0.01% 1083

Other funds holding CVKD

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return
HI
Harbour Investments Madison, Wisconsin $6.48B AUM 18.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Destiny Wealth Partners's CVKD Position: Q1 2026 in Review

Destiny Wealth Partners opened a new position in Cadrenal Therapeutics (CVKD) in Q1 2026: 200 shares worth $1.02K. The stake represents ﹤0.01% of the portfolio and ranks #1083 among its holdings.

20 funds tracked by Wall St. Rank hold CVKD as of Q1 2026.

  • Destiny Wealth Partners held 200 shares of Cadrenal Therapeutics worth $1.02K as of Q1 2026.
  • Cadrenal Therapeutics was a new Destiny Wealth Partners position in Q1 2026.
  • Cadrenal Therapeutics made up ﹤0.01% of Destiny Wealth Partners's portfolio in Q1 2026, its #1083 holding.
  • 20 funds tracked by Wall St. Rank held Cadrenal Therapeutics as of Q1 2026.

Based on Destiny Wealth Partners's 13F filing for Q1 2026, filed 11 May 2026.